Alyeska Investment Group’s Gilead Sciences GILD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q3
Sell
-44,661
Closed -$4.95M 642
2025
Q2
$4.95M Buy
+44,661
New +$4.75M 0.02% 426
2023
Q2
Sell
-641,805
Closed -$53.3M 578
2023
Q1
$53.3M Sell
641,805
-184,527
-22% -$15.3M 0.47% 67
2022
Q4
$70.9M Sell
826,332
-347,635
-30% -$27.5M 0.73% 33
2022
Q3
$72.4M Sell
1,173,967
-329,710
-22% -$20.8M 0.84% 20
2022
Q2
$92.9M Buy
1,503,677
+972,263
+183% +$60.2M 1.06% 12
2022
Q1
$31.6M Buy
+531,414
New +$34M 0.35% 98
2018
Q3
Sell
-24,658
Closed -$1.75M 439
2018
Q2
$1.75M Sell
24,658
-1,165,501
-98% -$82.3M 0.02% 360
2018
Q1
$89.7M Buy
+1,190,159
New +$94.6M 0.74% 33
2016
Q4
Sell
-127,437
Closed -$10.1M 495
2016
Q3
$10.1M Sell
127,437
-795,182
-86% -$64.6M 0.09% 266
2016
Q2
$77M Sell
922,619
-177,104
-16% -$15.7M 0.72% 26
2016
Q1
$101M Buy
+1,099,723
New +$99.2M 0.93% 17
2014
Q1
Sell
-110,000
Closed -$8.26M 352
2013
Q4
$8.26M Buy
110,000
+85,200
+344% +$5.93M 0.33% 115
2013
Q3
$1.56M Sell
24,800
-198,532
-89% -$11.9M 0.06% 244
2013
Q2
$11.4M Buy
+223,332
New +$11.6M 0.56% 52

Other funds holding GILD

Alyeska Investment Group's GILD Position: Q3 2025 in Review

Alyeska Investment Group sold out of Gilead Sciences (GILD) in Q3 2025, closing a stake of 44,661 shares — an estimated $4.95M sold.

Alyeska Investment Group first reported a position in GILD in Q2 2013 and held it in 14 quarters. The position peaked at $101M in Q1 2016. 2,026 funds tracked by Wall St. Rank hold GILD as of Q3 2025.

  • Alyeska Investment Group reported no remaining Gilead Sciences position as of Q3 2025 after selling out during the quarter.
  • Alyeska Investment Group sold 44,661 Gilead Sciences shares in Q3 2025, an estimated $4.95M.
  • Alyeska Investment Group first reported a position in Gilead Sciences in Q2 2013 and held it in 14 quarters.
  • Alyeska Investment Group's Gilead Sciences position peaked at $101M in Q1 2016.
  • 2,026 funds tracked by Wall St. Rank held Gilead Sciences as of Q3 2025.

Based on Alyeska Investment Group's 13F filing for Q3 2025, filed 17 Nov 2025.